KBY Biotech Indexv0.0.34
Search
← Pipeline|Fixatuximab

Fixatuximab

Phase 3
PAT-3676
By PathAI
Source: Trial-derived·Trials: 3
Modality
ASO
MOA
Cl18.2
Target
JAK1
Pathway
T-cell
Epilepsy
Development Pipeline
Preclinical
~Mar 2013
→ ~Jun 2014
Phase 1
~Sep 2014
→ ~Dec 2015
Phase 2
~Mar 2016
→ ~Jun 2017
Phase 3
Sep 2017
→ Jan 2029
Phase 3Current
NCT04762270
1,975 pts·Epilepsy
2023-04→2029-01·Completed
NCT04483859
2,168 pts·Epilepsy
2018-04→TBD·Completed
NCT07271608
2,476 pts·Epilepsy
2017-09→2027-08·Terminated
6,619 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-08-031.3y awayPh3 Readout· Epilepsy
2029-01-262.8y awayPh3 Readout· Epilepsy
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Termina…
P3
Complet…
P3
Complet…
Catalysts
Ph3 Readout
2027-08-03 · 1.3y away
Epilepsy
Ph3 Readout
2029-01-26 · 2.8y away
Epilepsy
CompletedTerminated|StartCompletionToday
Trials (3)
NCTPhaseIndicationStatusNEP
NCT04762270Phase 3EpilepsyCompleted1975FEV1
NCT04483859Phase 3EpilepsyCompleted2168eGFR
NCT07271608Phase 3EpilepsyTerminated2476EASI-75
Competitors (10)
DrugCompanyPhaseTargetMOA
IvorelsinEli LillyApprovedJAK1Menini
RHH-974RochePreclinicalJAK1MALT1i
ZorivorutinibBristol-Myers SquibbApprovedDLL3Cl18.2
FixatenlimabGSKPhase 1/2JAK1CDK4/6i
GIL-8529Gilead SciencesPhase 1/2JAK1EGFRi
ElrarapivirRegeneronPhase 1GIP-RCl18.2
HAL-9635HalozymePhase 2/3EZH2Cl18.2
VKT-6548Viking TherapeuticsPhase 2/3PD-L1Cl18.2
TiratapinarofIntelliaNDA/BLAAPOC3Cl18.2
MLY-3531MineralysNDA/BLAJAK1CD47i